Contact us for product
availability and pricing.

Welcome to InLighta BioSciences

Revolutionizing MRI
Contrast Agents for Disease
Detection and Tracking

About Us

InLighta BioSciences L.L.C. was formed in 2012 by Dr. Jenny J. Yang, to develop patented protein-based contrast agents for pre-clinical and clinical imaging applications.

Our precision Magnetic Resonance Imaging (pMRI) technology addresses current deficiencies in medical diagnostics for early detection, monitoring disease progression, image-guided intervention, and evaluating drug delivery and therapeutic treatment.

Protein-based Contrast Agents (ProCA®s) combined with pMRI technologies, provide significantly improved sensitivity and accuracy for assessing a broad range of diseases including cancers and fibrosis, and effective molecular MR imaging of multiple biomarkers for liver, lung, breast, ovarian, and prostate cancers, and liver metastases from uveal melanoma, breast, and ovarian cancers.

Our Products/ Services

MRI Contrast Agents

InLighta is currently developing high-contrast agents for MR imaging. The ProCA® series of contrast agents includes both blood pool agents and targeted contrast agents for specific biomarkers.


ProCA® Series

ProCA®’s are Protein-based Contrast Agents comprised of altered human protein scaffolds with engineered metal-chelating sites.
ProCA®’s can be utilized as blood-pool agents, or combined with targeting moieties for localized delivery via intravenous injection.
ProCA®s are designed to selectively and tightly bind gadolinium. The resulting stability prevents gadolinium from being replaced by physiological metals like calcium, magnesium, and zinc. This is a significant improvement over current clinical contrast agents, and significantly decreases toxicity risks.
While typical MRI contrast agents enhance imaging through either longitudinal or transverse relaxivity, ProCA®s exhibit high relaxivities for both, resulting in a dual imaging methodology that allows for more precise detection of smaller, early stage tissue abnormalities, that could not yet be detected by current contrast agents.


Blood Pool Agents

ProCA®32: Allows for imaging liver tumors that measure less than 0.25 millimeters.
More than 40 times more sensitive than today’s commonly used and clinically-approved agents used to detect tumors in the liver.
In addition to contrast specificity within the liver, ProCA®32 provides full-body contrast as a blood pool agent.
ProCA®32 is currently available for non-clinical laboratory use.


Targeted Contrast Agents

Targeted Biomarkers:

Collagen: Structural protein provides strength and elasticity to tissues

EGFR: Cell surface receptor regulating cell growth and division

HER2: Cell receptor in cell growth, linked to breast cancer.

PSMA: Overexpressed in prostate cancer, used for imaging and therapy.

Integrin: Cell adhesion receptors, crucial for cell attachment and signaling.

CXCR4: Chemokine receptor, guides cell migration, implicated in diseases..

CXCR12: Chemokine ligand regulating immune responses and migration.

GRPR: Found in gastrointestinal tissues, targeted in cancer imaging and treatment

Who We Are

Dr. Jenny Yang

Dr. Jenny Yang

President and Founder

Business Advisory Board

Dr. David Xue

Dr. David Xue

Research scientist, product & technology

Science Advisory Board

Business Advisory Board

Business Advisory Board


Science Advisory Board

Science Advisory Board


Explore More

InLighta BioSciences IN THE NEWS

Our Sponsors / Investors

Our Valuable Resources

Conflict of interest policy

Get in Touch

For additional information on products, services, or investment opportunities, please contact us using the form below.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Contact Information

InLighta BioSciences L.L.C.
Atlanta, GA 30303

Dr. Jenny J. Yang

Dr. Jina Qiao